triamcinolone acetonide + prednisone

triamcinolone acetonide + prednisone is a combination corticosteroid regimen developed and investigated by researchers at Peking University First Hospital for the prevention of esophageal stricture following extensive endoscopic submucosal dissection (ESD). The regimen typically involves the localized, intralesional injection of triamcinolone acetonide—a potent, long-acting synthetic glucocorticoid—directly into the ulcer bed created by the ESD procedure, supplemented by a tapering course of oral prednisone. Both agents act as agonists of the glucocorticoid receptor, which mediates the suppression of inflammatory cytokines and the inhibition of fibroblast proliferation and collagen synthesis. By targeting both local and systemic inflammatory pathways, this combination therapy aims to reduce the high incidence of post-operative scarring and lumen narrowing in patients with early esophageal neoplasms.

Other names

oral prednisone plus intralesional triamcinolone acetonide